Despite positive clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial difficulty from managed care entities. The companies are https://jonashgme292213.fitnell.com/83144404/company-s-vyndamax-faces-is-encountering-pbm-challenges-a-copyrightination-at-reimbursement-fights